Mylan Inc (MYL-Q) Stock Predictions - Stockchase
WATCH LIST
9
Mylan Inc (MYL-Q)

ON STOCKCHASE SINCE Oct 2004

biotechnology/pharmaceutical

Mylan Inc

MYL-Q

0 watching          
Join the Discussion

Mylan Inc (MYL-Q) SAVE Apr, 22, 2019, 11:21 am

26.56 0.3 (1.1%)

About Mylan Inc (MYL-Q)

Mylan N.V. is an American global generic and specialty pharmaceuticals company registered in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and global headquarters in Canonsburg, Pennsylvania, US. More at Wikipedia

What the experts are saying about MYL-Q



  • All
  • Filtered
Signal Opinion Expert
DON'T BUY
Mylan Inc(MYL-Q) 

August 10, 2017

TEVA-N vs. MYL-Q. He does not like either at these prices.  They are both generics manufacturers. There are lots of headwinds on pricing in these categories. We have had a lot of noise on pricing of pharmaceuticals.  The FDA is going to alleviate the delays on getting new drugs to market.  He wants to be in pharmas that have innovation.  He is concerned about how their business model will fair over the next 5 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

TEVA-N vs. MYL-Q. He does not like either at these prices.  They are both generics manufacturers. There are lots of headwinds on pricing in these categories. We have had a lot of noise on pricing of pharmaceuticals.  The FDA is going to alleviate the delays on getting new drugs to market.  He wants to be in pharmas that have innovation.  He is concerned about how their business model will fair over the next 5 years.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Lauzon

Deputy Chi, Middlefield Capital ...

Price Price
$32.290
Owned Owned
Unknown

PAST TOP PICK
Mylan Inc(MYL-Q) 

February 22, 2017

(A Top Pick Feb 8/16. Down 16.58%.) Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). Unfortunately both stocks came down.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Feb 8/16. Down 16.58%.) Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). Unfortunately both stocks came down.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jerome Hass

Portfolio , Lightwater Partners...

Price Price
$42.000
Owned Owned
Yes

HOLD
Mylan Inc(MYL-Q) 

January 30, 2017

Epi Pens.  They are very expensive, $600 each.  They then offered a $300 generic version.  There are now competitors, but they own 90% of the market place.  The stock took a bit of a hit, but she still likes it and thinks they will keep market share even if prices come down a bit for Epi Pens. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Epi Pens.  They are very expensive, $600 each.  They then offered a $300 generic version.  There are now competitors, but they own 90% of the market place.  The stock took a bit of a hit, but she still likes it and thinks they will keep market share even if prices come down a bit for Epi Pens. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Erin Gibbs

V.P., S&P Global Market In...

Price Price
$36.340
Owned Owned
Unknown

DON'T BUY
Mylan Inc(MYL-Q) 

January 30, 2017

People really hate this, and unfortunately it has become one of the poster children of aggressive drug pricing, high compensation of the C suite, the EpiPen debacle, and kind of a lacklustre performance. Thinks this is going to be under a lot of pressure. He would suggest that you switch into Celgene (CELG-Q).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

People really hate this, and unfortunately it has become one of the poster children of aggressive drug pricing, high compensation of the C suite, the EpiPen debacle, and kind of a lacklustre performance. Thinks this is going to be under a lot of pressure. He would suggest that you switch into Celgene (CELG-Q).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Stephenson

President , Stephenson & Company...

Price Price
$36.340
Owned Owned
Unknown

PAST TOP PICK
Mylan Inc(MYL-Q) 

December 29, 2016

(A Top Pick Feb 8/16. Down 25.9%.) Long. (A Pairs trade with Valeant Pharmaceuticals (VRX-T).)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Feb 8/16. Down 25.9%.) Long. (A Pairs trade with Valeant Pharmaceuticals (VRX-T).)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jerome Hass

Portfolio , Lightwater Partners...

Price Price
$37.380
Owned Owned
Yes

BUY
Mylan Inc(MYL-Q) 

December 23, 2016

They jacked up the price of the EpiPen and it gave a whole credibility issue problem to the company and brought it under some pressure. Healthcare and technology are those things that are going to grow in almost any market environment over the next number of years. This company is pretty well positioned. They argued their case effectively.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They jacked up the price of the EpiPen and it gave a whole credibility issue problem to the company and brought it under some pressure. Healthcare and technology are those things that are going to grow in almost any market environment over the next number of years. This company is pretty well positioned. They argued their case effectively.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Zechner

Chairman, J. Zechner & Assoc...

Price Price
$37.500
Owned Owned
Unknown

PAST TOP PICK
Mylan Inc(MYL-Q) 

October 4, 2016

(An update from Jerome!) (A Top Pick Feb 8/16.) Long. He covered this on Aug 25/16. This is not a name he would probably go back to.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(An update from Jerome!) (A Top Pick Feb 8/16.) Long. He covered this on Aug 25/16. This is not a name he would probably go back to.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jerome Hass

Portfolio , Lightwater Partners...

Price Price
$37.970
Owned Owned
No

TOP PICK
Mylan Inc(MYL-Q) 

February 8, 2016

Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). In a Pair trade you really have conviction on both sides. In this instance, while he likes Mylan as a Long hedge position, the conviction actually lies with Valeant as a Short, which still has a lot of fundamental problems ahead of them.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Long. (A Pairs trade with a Short on Valeant Pharma (VRX-T). In a Pair trade you really have conviction on both sides. In this instance, while he likes Mylan as a Long hedge position, the conviction actually lies with Valeant as a Short, which still has a lot of fundamental problems ahead of them.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jerome Hass

Portfolio , Lightwater Partners...

Price Price
$50.450
Owned Owned
Yes

BUY
Mylan Inc(MYL-Q) 

October 7, 2004

Recently acquired King Pharmaceuticals.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Recently acquired King Pharmaceuticals.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$17.390
Owned Owned
Yes

Showing 1 to 9 of 9 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days